RESUMEN
BACKGROUND: The antibacterial effect of antibiotics is linked to the free drug concentration. This study investigated the applicability of an ultrafiltration method to determine free plasma concentrations of beta-lactam antibiotics in ICU patients. METHODS: Eligible patients included adult ICU patients treated with ceftazidime (CAZ), meropenem (MEM), piperacillin (PIP)/tazobactam (TAZ), or flucloxacillin (FXN) by continuous infusion. Up to 2 arterial blood samples were drawn at steady state. Patients could be included more than once if they received another antibiotic. Free drug concentrations were determined by high-performance liquid chromatography with ultraviolet detection after ultrafiltration, using a method that maintained physiological conditions (pH 7.4/37°C). Total drug concentrations were determined to calculate the unbound fraction. In a post-hoc analysis, free concentrations were compared with the target value of 4× the epidemiological cut-off value (ECOFF) for Pseudomonas aeruginosa as a worst-case scenario for empirical therapy with CAZ, MEM or PIP/tazobactam and against methicillin-sensitive Staphylococcus aureus for targeted therapy with FXN. RESULTS: Fifty different antibiotic treatment periods in 38 patients were evaluated. The concentrations of the antibiotics showed a wide range because of the fixed dosing regimen in a mixed population with variable kidney function. The mean unbound fractions (fu) of CAZ, MEM, and PIP were 102.5%, 98.4%, and 95.7%, with interpatient variability of <6%. The mean fu of FXN was 11.6%, with interpatient variability of 39%. It was observed that 2 of 12 free concentrations of CAZ, 1 of 40 concentrations of MEM, and 11 of 23 concentrations of PIP were below the applied target concentration of 4 × ECOFF for P. aeruginosa. All concentrations of FXN (9 samples from 6 patients) were >8 × ECOFF for methicillin-sensitive Staphylococcus aureus. CONCLUSIONS: For therapeutic drug monitoring purposes, measuring total or free concentrations of CAZ, MEM, or PIP is seemingly adequate. For highly protein-bound beta-lactams such as FXN, free concentrations should be favored in ICU patients with prevalent hypoalbuminemia.
Asunto(s)
Antibacterianos , Adulto , Antibacterianos/sangre , Antibacterianos/uso terapéutico , Ceftazidima/sangre , Ceftazidima/uso terapéutico , Floxacilina/sangre , Floxacilina/uso terapéutico , Humanos , Unidades de Cuidados Intensivos , Meropenem/sangre , Meropenem/uso terapéutico , Combinación Piperacilina y Tazobactam/sangre , Combinación Piperacilina y Tazobactam/uso terapéutico , Pseudomonas aeruginosa , Staphylococcus aureusRESUMEN
Pharmacokinetic/pharmacodynamic indices of anti-infective drugs should be referenced to free drug concentrations. In the present study, clindamycin, flucloxacillin and tedizolid have been determined in human plasma by HPLC-UV. The drugs were separated isocratically within 3-6 min on a C18 column using mixtures of phosphate buffer-acetonitrile of pH 7.1-7.2. Sample treatment for the determination of total drug concentrations in plasma included extraction/back-extraction (clindamycin) or protein precipitation (flucloxacillin, tedizolid). The free drug concentrations were determined after ultrafiltration. An ultrafiltration device with a membrane consisting of regenerated cellulose proved to be suitable for all drugs. Maintaining a physiological pH was crucial for clindamycin, whereas maintaining body temperature was essential for tedizolid. The methods were applied to the analysis of total and free drug concentrations in clinical samples and were sufficiently sensitive for pharmacokinetic studies and therapeutic drug monitoring.
Asunto(s)
Clindamicina/sangre , Floxacilina/sangre , Oxazolidinonas/sangre , Tetrazoles/sangre , Ultrafiltración , Cromatografía Líquida de Alta Presión/métodos , Clindamicina/química , Clindamicina/aislamiento & purificación , Monitoreo de Drogas , Floxacilina/química , Floxacilina/aislamiento & purificación , Humanos , Modelos Lineales , Oxazolidinonas/química , Oxazolidinonas/aislamiento & purificación , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Espectrofotometría Ultravioleta , Tetrazoles/química , Tetrazoles/aislamiento & purificaciónRESUMEN
AIMS: Flucloxacillin dosing may be guided by measurement of its total plasma concentrations. Flucloxacillin is highly protein bound with fraction unbound in plasma (fu ) of around 0.04 in healthy individuals. The utility of measuring unbound flucloxacillin concentrations for patients outside the intensive care unit (ICU) is not established. We aimed to compare flucloxacillin fu in non-ICU hospitalised patients against healthy volunteers, and to examine the performance of a published model for predicting unbound concentrations, using total flucloxacillin and plasma albumin concentrations. METHODS: Data from 12 healthy volunteers (248 samples) and 47 hospitalized patients (61 samples) were examined. Plasma flucloxacillin concentrations were measured using a validated liquid chromatography-tandem mass spectrometry method. Flucloxacillin fu for the two groups was compared using a generalized estimating equation model to account for clustered observations. The performance of the single protein binding site prediction model in hospitalized patients was compared with measured unbound concentrations using Bland-Altman plots. RESULTS: The median (range) flucloxacillin fu for healthy (median albumin 45 g l-1 ) and hospitalized individuals (median albumin 30 g l-1 ) were 0.04 (0.02-0.07) and 0.10 (0.05-0.37), respectively (P < 0.0001). The prediction model underpredicted unbound flucloxacillin concentrations with a mean bias (95% limits of agreement) of -54% (-137%, +30%). CONCLUSIONS: The flucloxacillin fu values observed in our cohort of hospitalized patients had a wide range and were greater than those of healthy individuals. Unbound flucloxacillin plasma concentrations were predicted poorly by the model. Instead, unbound concentrations should be measured to guide dosing.
Asunto(s)
Antibacterianos/farmacocinética , Bacteriemia/tratamiento farmacológico , Floxacilina/farmacocinética , Modelos Biológicos , Infecciones Estafilocócicas/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Bacteriemia/microbiología , Cromatografía Líquida de Alta Presión/métodos , Relación Dosis-Respuesta a Droga , Femenino , Floxacilina/administración & dosificación , Floxacilina/sangre , Voluntarios Sanos , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Plasma/química , Albúmina Sérica Humana/análisis , Infecciones Estafilocócicas/sangre , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/aislamiento & purificación , Espectrometría de Masas en Tándem/métodos , Adulto JovenRESUMEN
Penicillins are widely used to treat infections in children; however, the evidence is continuing to evolve in defining the optimal dosing. Modern pediatric pharmacokinetic study protocols frequently favor opportunistic, "scavenged" sampling. This study aimed to develop a small-volume single assay for five major penicillins and to assess the influence of sample degradation on inferences made using pharmacokinetic modeling, to investigate the suitability of scavenged sampling strategies. Using a rapid ultrahigh-performance liquid chromatographic-tandem mass spectrometric method, an assay for five penicillins (amoxicillin, ampicillin, benzylpenicillin, piperacillin, and flucloxacillin) in blood plasma was developed and validated. Penicillin stabilities were evaluated under different conditions. Using these data, the impact of drug degradation on inferences made during pharmacokinetic modeling was evaluated. All evaluated penicillins indicated good stability at room temperature (23 ± 2°C) over 1 h, remaining in the range of 98 to 103% of the original concentration. More-rapid analyte degradation had already occurred after 4 h, with stability ranging from 68% to 99%. Stability over longer periods declined: degradation of up to 60% was observed with delayed sample processing of up to 24 h. Modeling showed that analyte degradation can lead to a 30% and 28% bias in clearance and volume of distribution, respectively, and falsely show nonlinearity in clearance. Five common penicillins can now be measured in a single low-volume blood sample. Beta-lactam chemical instability in plasma can cause misleading pharmacokinetic modeling results, which could impact upon model-based dosing recommendations and the forthcoming era of beta-lactam therapeutic drug monitoring.
Asunto(s)
Amoxicilina/sangre , Ampicilina/sangre , Antibacterianos/sangre , Floxacilina/sangre , Penicilina G/sangre , Piperacilina/sangre , Cromatografía Líquida de Alta Presión , Estabilidad de Medicamentos , Humanos , Espectrometría de Masas en TándemRESUMEN
Objectives: To determine the existence of concentration-toxicity relationships for common ß-lactam antibiotic adverse effects and define thresholds above which toxicity is more likely. Patients and methods: Retrospective review of consecutive patients treated with piperacillin, meropenem or flucloxacillin who underwent therapeutic drug monitoring (TDM) at St Vincent's Hospital (Sydney, Australia) between January 2013 and December 2015. Adverse events investigated included neurotoxicity, nephrotoxicity, hepatotoxicity and opportunistic Clostridium difficile infection. Toxicity was measured using observational grading criteria, clinical assessment and relevant serum biomarkers. These findings were correlated with trough TDM measurements at the time of toxicity presentation. Results: TDM results from 378 patients (piperacillin = 223, meropenem = 94 and flucloxacillin = 61) were investigated. There was no difference in baseline patient characteristics across antibiotic groups. A statistically significant elevation in mean serum trough concentrations (Cmin) was found in patients diagnosed with neurotoxicity (piperacillin, P < 0.01; meropenem, P = 0.04; flucloxacillin, P = 0.01) and those who developed nephrotoxicity whilst being treated with piperacillin (P < 0.01) or meropenem (P < 0.01). Incidence of hepatotoxicity and C. difficile was not related to Cmin. Threshold concentrations for which there is 50% risk of developing a neurotoxicity event (piperacillin, Cmin >361.4 mg/L; meropenem, Cmin >64.2 mg/L; flucloxacillin, Cmin >125.1 mg/L) or nephrotoxicity (piperacillin, Cmin >452.65 mg/L; meropenem, Cmin >44.45 mg/L) varied across antibiotics. Conclusions: Our data reveal an association between toxic concentrations for a number of ß-lactam agents and neurotoxic/nephrotoxic effects. We have defined threshold concentrations above which these toxicities become more likely. Clinicians should balance concerns for therapeutic efficacy with potential toxicity when considering aggressive therapy.
Asunto(s)
Antibacterianos/efectos adversos , beta-Lactamas/efectos adversos , Adulto , Anciano , Antibacterianos/sangre , Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Infecciones por Clostridium/etiología , Estudios de Cohortes , Monitoreo de Drogas , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Femenino , Floxacilina/efectos adversos , Floxacilina/sangre , Floxacilina/uso terapéutico , Humanos , Incidencia , Masculino , Meropenem , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Síndromes de Neurotoxicidad/diagnóstico , Síndromes de Neurotoxicidad/etiología , Piperacilina/efectos adversos , Piperacilina/sangre , Piperacilina/uso terapéutico , Estudios Retrospectivos , Tienamicinas/efectos adversos , Tienamicinas/sangre , Tienamicinas/uso terapéutico , beta-Lactamas/sangre , beta-Lactamas/uso terapéuticoRESUMEN
OBJECTIVE: To report the difficulty in achieving and maintaining target antibiotic exposure in critically ill patients with deep-seeded infections. CASE SUMMARY: We present a case of a 36-year-old man who was admitted to the intensive care unit with diffuse central nervous system and peripheral methicillin-sensitive Staphylococcus aureus infection (minimum inhibitory concentration; MIC, 1 µg/mL). Owing to the complicated nature of the infection, sequential concentrations of free flucloxacillin were measured in plasma and cerebrospinal fluid (CSF) and used to direct antibiotic dosing. Unsurprisingly, the trough plasma concentrations of flucloxacillin were below the MIC (0.2-0.4 µg/mL), and the corresponding CSF concentrations were undetectable (<0.1 µg/mL) with standard intermittent bolus dosing of 2 g every 4 hours. By administering flucloxacillin by continuous infusion (CI) and increasing the dose to 20 g daily, the plasma (2.2-5.7 µg/mL) and CSF (0.1 µg/mL) levels were increased, albeit lower than the predefined targets (plasma, 40 µg/mL; CSF, 4 µg/mL). DISCUSSION: The presence of physiological changes associated with critical illness-namely, hypoalbuminemia and augmented renal clearance-may significantly alter antibiotic pharmacokinetics, and this phenomenon may lead to suboptimal antibiotic exposure if they are not accounted for. This case also highlights the value of applying CI in such patient groups and demonstrates the significance of monitoring plasma and CSF drug concentrations in optimizing antibiotic delivery. CONCLUSIONS: Future research should aim to evaluate the utility of such drug monitoring with regard to patient outcomes and cost-effectiveness.
Asunto(s)
Antibacterianos/sangre , Antibacterianos/líquido cefalorraquídeo , Infecciones Bacterianas del Sistema Nervioso Central/tratamiento farmacológico , Floxacilina/sangre , Floxacilina/líquido cefalorraquídeo , Infecciones Estafilocócicas/tratamiento farmacológico , Adulto , Antibacterianos/administración & dosificación , Infecciones Bacterianas del Sistema Nervioso Central/sangre , Infecciones Bacterianas del Sistema Nervioso Central/líquido cefalorraquídeo , Enfermedad Crítica , Monitoreo de Drogas , Floxacilina/administración & dosificación , Humanos , Infusiones Intravenosas , Unidades de Cuidados Intensivos , Masculino , Pruebas de Sensibilidad Microbiana , Infecciones Estafilocócicas/sangre , Infecciones Estafilocócicas/líquido cefalorraquídeo , Staphylococcus aureus/efectos de los fármacosRESUMEN
PURPOSE: CYP3A4 is the main isoform of cytochrome P450 oxidases involved in the metabolism of approximately 60 % drugs, and its expression level is highly variable in human subjects. CYP3A4 is regulated by many transcription factors, among which the pregnane X receptor/steroid and xenobiotic receptor (PXR/SXR, NR1I2) have been identified as the most critical. Genetic polymorphisms (such as SNPs) in PXR may affect the expression level of CYP3A4. Although numerous SNPs have been identified in PXR and have appeared to affect PXR function, their impact on the expression of CYP3A4 in human subjects has not been well studied. Thus, a clinical study in healthy Chinese subjects was conducted to investigate the impact of PXR polymorphisms on repaglinide (an endogenous marker for CYP3A4 activity) pharmacokinetics used alone or in combination with a PXR inducer, flucloxacillin. METHOD: Two SNPs, -298A>G and 11193T>C, were identified as the tag SNPs to represent the overall genetic polymorphic profile of PXR. To evaluate the potential functional change of these two SNPs, 24 healthy subjects were recruited in a pharmacokinetics/pharmacodynamics study of repaglinide with or without flucloxacillin. RESULTS: The pharmacokinetic parameters including AUC and T1/2 were significantly different among the PXR genotype groups. The SNPs of -298G/G and 11193C/C were found to be associated with a lower PXR activity resulting in reduction of CYP3A4 activity in vivo. After administration of flucloxacillin, a significant drug-drug interaction was observed. The clearance of repagnilide was significantly increased by concomitant flucloxacillin in a genotype dependent manner. The subjects with SNPs of -298G/G and 11193C/C appeared to be less sensitive to flucloxacillin. CONCLUSION: Our study results demonstrated for the first time the impact of genetic polymorphisms of PXR on the PK and PD of repaglinide, and showed that subjects with genotype of -298G/G and 11193C/C in PXR has a decreased elimination rate of 3A4/2C8. Furthermore, flucloxacillin was able to induce 3A4/2C8 expression mediated by PXR in a genotype dependent manner.
Asunto(s)
Antibacterianos/farmacología , Carbamatos/farmacología , Floxacilina/farmacología , Hipoglucemiantes/farmacología , Piperidinas/farmacología , Receptores de Esteroides/genética , Antibacterianos/sangre , Hidrocarburo de Aril Hidroxilasas/genética , Pueblo Asiatico/genética , Glucemia/análisis , Carbamatos/sangre , Estudios Cruzados , Citocromo P-450 CYP2C8 , Citocromo P-450 CYP3A/genética , Interacciones Farmacológicas , Floxacilina/sangre , Genotipo , Voluntarios Sanos , Humanos , Hipoglucemiantes/sangre , Piperidinas/sangre , Polimorfismo de Nucleótido Simple , Receptor X de Pregnano , Receptores de Esteroides/metabolismoRESUMEN
BACKGROUND: Patients with severe methicillin-sensitive Staphylococcus aureus infections are effectively treated with initial continuous intravenous (iv) flucloxacillin followed by oral maintenance therapy. As the absorption of oral flucloxacillin is variable, an oral absorption test (OAT) is used to ensure efficacious therapy. The classical OAT (test A) requires overnight fasting, interruption of iv therapy, and is laborious. We designed a simplified OAT (test B) in which iv therapy is continued and oral dosing is performed after a 1-hour fast. METHODS: In 43 hospitalized patients on iv flucloxacillin, either test A or test B was performed. In each variant, 1 g of oral flucloxacillin was given, and blood samples were taken before and at 1 and 2 hours after dosing. Flucloxacillin concentration was determined by high-performance liquid chromatography. Adequate absorption was defined as a ≥ 10 mg/L increase in flucloxacillin concentration at 1 or 2 hours after dosing. RESULTS: In a population of 43 patients (18F/25M), test A was done in 19 patients and test B in 24 patients. The groups had similar baseline characteristics such as age, renal function, gender, diagnoses, or comedication. All the patients tolerated the test without problems. The absorption was highly variable between patients. The average (SD; range) maximal increase for test A was 22.3 (11.6; 7-50) mg/L and 26.5 (12.6; 8-53) mg/L for test B. There was no significant difference between the 2 tests (P = 0.23), and 10% of the patients were poor absorbers (increase <10 mg/L). There was no influence of serum creatinine, age, or pretest flucloxacillin concentration. No clinical condition or drug use that may have impaired flucloxacillin absorption could be identified. CONCLUSIONS: We designed a simplified OAT that performs well and can be implemented easily. This test may be helpful to rationally and effectively treat patients with severe methicillin-sensitive S. aureus infections with an orally administered small-spectrum antibiotic.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/sangre , Floxacilina/administración & dosificación , Floxacilina/sangre , Absorción Intestinal/fisiología , Administración Oral , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Humanos , Infusiones Intravenosas , Absorción Intestinal/efectos de los fármacos , Masculino , Persona de Mediana Edad , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
A novel method has been developed for the simultaneous determination of flucloxacillin and ampicillin in human plasma by ultra performance liquid chromatography combined with tandem mass spectrometry (UPLC-MS/MS). The plasma was treated by single step of protein precipitation (PPT) with acetonitrile. The chromatographic separation was performed with a mobile phase consisting of 10mM ammonium formate and acetonitrile (68:32, v/v). The analyses were carried out by multiple reaction monitoring (MRM) using the precursor-to-product combinations of m/z 454.1â160.3 (flucloxacillin), m/z 350.1â106.4 (ampicillin) and m/z 436.1â277.3 (IS). Validation results indicated that the lower limit of quantification (LLOQ) were both 0.2 µg/mL and both assay exhibited a linear range of 0.2-500 µg/mL. The intra-batch precision (R.S.D.) was less than 10.6% and inter-batch R.S.D. was less than 11.2%, while accuracy was with ±8% and ±9.9%, determined from QC samples for flucloxacillin and ampicillin. A rapid, sensitive and specific method for simultaneous quantifying flucloxacillin and ampicillin in human plasma have been devised and successfully applied to a clinic pharmacokinetic study.
Asunto(s)
Ampicilina/sangre , Antibacterianos/sangre , Cromatografía Líquida de Alta Presión/métodos , Floxacilina/sangre , Espectrometría de Masas en Tándem/métodos , Adulto , Ampicilina/farmacocinética , Antibacterianos/farmacocinética , Calibración , China , Cromatografía Líquida de Alta Presión/instrumentación , Estabilidad de Medicamentos , Floxacilina/farmacocinética , Humanos , Límite de Detección , Modelos Lineales , Estándares de Referencia , Reproducibilidad de los Resultados , Espectrometría de Masas en Tándem/instrumentación , Adulto JovenRESUMEN
AIMS: To explore the extent, time course, site(s), mechanism and possible clinical relevance of the pharmacokinetic (PK) interaction between piperacillin and flucloxacillin. METHODS: A single-dose, randomized, six-way crossover study in 10 healthy volunteers where all subjects received all of the following as 5-min intravenous infusions: (i) 1.5 g piperacillin, (ii) 0.5 g flucloxacillin, (iii) 1.5 g piperacillin + 0.5 g flucloxacillin, (iv) 3 g piperacillin, (v) 1 g flucloxacillin, and (vi) 3 g piperacillin + 1 g flucloxacillin. Drug concentrations in plasma and urine were determined by high-performance liquid chromatography. WinNonlin was used for PK modelling and statistics. RESULTS: Piperacillin significantly decreased the renal clearance of flucloxacillin from 5.44 to 2.29 l h(-1) (medians, P < 0.01) and the nonrenal clearance of flucloxacillin from 2.67 to 1.80 l h(-1) (P < 0.01). The renal clearance of flucloxacillin was reduced to 45% (point estimate, 90% confidence interval 40 to 50%) and the nonrenal clearance to 66% (59, 73). The extent of interaction was larger at the higher doses. Competitive inhibition of tubular secretion by piperacillin was identified as the most likely mechanism for the decreased renal clearance of flucloxacillin. Piperacillin had a 15-times higher affinity for the renal transporter than flucloxacillin based on the molar ratio. Piperacillin PK was only slightly affected by flucloxacillin. CONCLUSIONS: Piperacillin inhibits renal and nonrenal elimination of flucloxacillin. This interaction seems clinically significant, as total clearance was reduced by a factor of 1.5 for the lower and 2.1 for the higher doses. PK interactions, especially with piperacillin, are likely to occur also with other beta-lactam combinations and might be useful to improve the effectiveness of antibacterial treatment.
Asunto(s)
Antibacterianos/farmacología , Floxacilina/farmacología , Túbulos Renales/metabolismo , Piperacilina/farmacología , Adulto , Análisis de Varianza , Antibacterianos/sangre , Antibacterianos/orina , Área Bajo la Curva , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Interacciones Farmacológicas , Femenino , Floxacilina/sangre , Floxacilina/orina , Humanos , Infusiones Intravenosas , Pruebas de Función Renal , Túbulos Renales/efectos de los fármacos , Masculino , Tasa de Depuración Metabólica , Modelos Químicos , Piperacilina/sangre , Piperacilina/orina , Adulto JovenRESUMEN
Simple and rapid reversed-phase high-performance liquid chromatographic assays with ultraviolet detection have been developed and validated for the determination of amoxicillin, flucloxacillin and rifampicin in neonatal plasma. Plasma samples were either precipitated with perchloric acid (amoxicillin) or methanol (rifampicin) or extracted with methylene chloride (flucloxacillin). Precision coefficients of variation and inaccuracy were less than 15% for all three assays. Only small sample volumes (20-40 microL) were required, making the assays suitable for therapeutic drug monitoring and pharmacokinetic studies in preterm and term neonates. The assays have successfully been applied to analysis of amoxicillin, flucloxacillin and rifampicin in previously published pharmacokinetic studies in neonates.
Asunto(s)
Amoxicilina/sangre , Antibacterianos/sangre , Floxacilina/sangre , Rifampin/sangre , Amoxicilina/farmacocinética , Amoxicilina/uso terapéutico , Antibacterianos/farmacocinética , Antibacterianos/uso terapéutico , Cromatografía Líquida de Alta Presión/métodos , Monitoreo de Drogas/métodos , Floxacilina/farmacocinética , Floxacilina/uso terapéutico , Humanos , Recién Nacido , Recien Nacido Prematuro , Rifampin/farmacocinética , Rifampin/uso terapéutico , Sensibilidad y Especificidad , Espectrofotometría Ultravioleta/métodosRESUMEN
The isoxazolyl penicillins, including flucloxacillin, have the highest levels of plasma protein binding among the semisynthetic penicillins. Because only the free fraction of the penicillin is pharmacologically active, it would be useful to measure both protein-bound and free flucloxacillin to determine its protein binding. Until now, flucloxacillin protein binding in newborn infants has been investigated in only two studies with relatively small populations. In the present study, flucloxacillin protein binding was investigated in 56 (preterm) infants aged 3 to 87 days (gestational age, 25-41 weeks). Surplus plasma samples from routine gentamicin assays of each infant were collected and combined to obtain a sufficiently large sample for analysis. Free flucloxacillin was separated from protein-bound flucloxacillin using ultrafiltration. Reversed-phase high-performance liquid chromatography with ultraviolet detection was used to measure free flucloxacillin concentrations in ultrafiltrate and total flucloxacillin concentrations in pooled plasma. Flucloxacillin protein binding was 74.5% +/- 13.1% (mean +/- standard deviation) with a high variability among the infants (34.3% to 89.7%). High Pearson correlations were found between protein binding and the covariates-plasma albumin concentration (r = 0.804, P < 0.001, n = 18) and plasma creatinine concentration (r = -0.601, P < 0.001, n = 45). Statistically significant but less striking correlations were found between protein binding and gestational age, postconceptional age, body weight, and triglyceride concentration. Because of the high variability of protein binding among infants, it is difficult to devise a flucloxacillin dosage regimen effective for all infants. Individualized dosing, based on free flucloxacillin concentrations, might help to optimize treatment of late-onset neonatal sepsis, but practical obstacles will probably prevent analysis of free flucloxacillin concentrations in newborn infants on a routine basis.
Asunto(s)
Antibacterianos/metabolismo , Floxacilina/metabolismo , Albúminas/metabolismo , Antibacterianos/sangre , Antibacterianos/uso terapéutico , Cromatografía Líquida de Alta Presión , Monitoreo de Drogas/métodos , Femenino , Floxacilina/sangre , Floxacilina/uso terapéutico , Humanos , Recién Nacido , Recien Nacido Prematuro , Masculino , Unión Proteica , Sepsis/sangre , Sepsis/tratamiento farmacológicoRESUMEN
A RP-HPLC method with rapid sample processing was developed for quantitation of flucloxacillin in human plasma using dicloxacillin as the internal standard. The plasma sample (100 microL) was acidified with glacial acetic acid, and deproteinized by precipitation with acetonitrile. The supernatant was directly injected into the HPLC system. Separation was achieved on an Alltima C18 column (250 mmx4.6 mm I.D., 5 microm), with a mixture of 10 mmol x L(-1) KH2PO4-acetonitrile (64.5:35.5, v/v) as mobile phase. The assay was successfully applied to a randomized, two-period cross-over bioequivalence study in 20 healthy Chinese volunteers following a single oral dose of 250 mg flucloxacillin capsules. A non-compartmental method was used for pharmacokinetic analysis. Compared with data in the literature, flucloxacillin was eliminated more slowly in Chinese than in Caucasians. Cmax, AUC(0-t) and AUC(0-infinity) were tested for bioequivalence after log-transformation of data. No significant difference was found. Tmax was analyzed by Wilcoxon's test and no significant difference was obtained (P > 0.05). Based on these statistical inferences, the two formulations were judged to be bioequivalent and, thus, can be prescribed interchangeably.
Asunto(s)
Floxacilina/sangre , Penicilinas/sangre , Adulto , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Floxacilina/farmacocinética , Humanos , Indicadores y Reactivos , Masculino , Penicilinas/farmacocinética , Control de Calidad , Estándares de Referencia , Reproducibilidad de los Resultados , Equivalencia TerapéuticaRESUMEN
In total 235 flucloxacillin total (free+protein bound) plasma concentrations were determined in 55 neonates (gestational age 26 to 42 weeks, postnatal age 0 to 44 days) with reversed-phase HPLC in surplus plasma samples from routine gentamicin assays. Population pharmacokinetic parameters were calculated according to an one compartment open model with iterative two-stage Bayesian fitting (MWPHARM 3.50, Mediware, The Netherlands). Mean clearance corrected for weight was 0.18+/-0.10 L kgh and volume of distribution corrected for weight was 0.54+/-0.17 L/kg. Pearson correlations between the individual pharmacokinetic parameters and covariates, like gestational age, plasma creatinine, and gentamicin clearance, were low and therefore not relevant for use in clinical practice. Total plasma concentrations above 200 mg/L were considered toxic and T>MIC (time above minimum inhibitory free plasma concentration) of more than 40% was considered effective. Protein binding was assumed to be 86.3% in all neonates, based on literature. The current dosage regimen, 25 or 50 mg/kg every 8 or 12 hours, did not result in effective plasma concentrations for the treatment of Staphylococcus aureus in 17 (31%) of the 55 neonates. Therefore, the authors suggest an initial dose of 25 mg/kg/4 h for all neonates, irrespective of their age, based on the breakpoint MIC value of flucloxacillin for Staphylococcus aureus (2.0 mg/L). After isolation of the causative agent of infection, flucloxacillin administration ought to be reconsidered based on the expected susceptibility pattern of the isolate. When oxacillin sensitive coagulase negative staphylococci are isolated, the initial dose should be reduced to 10 mg/kg/6 h, based on the breakpoint MIC value of 0.25 mg/L. Simulation with these new dosage regimens indicated that satisfactory plasma concentrations were reached in 52 of the 55 neonates. However, the regimens need prospective verification. Moreover, the exact role of neonatal protein binding needs to be further investigated.
Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Floxacilina/administración & dosificación , Floxacilina/farmacocinética , Antibacterianos/sangre , Cromatografía Líquida de Alta Presión , Monitoreo de Drogas , Femenino , Floxacilina/sangre , Gentamicinas/administración & dosificación , Semivida , Humanos , Lactante , Recién Nacido , Recien Nacido Prematuro , Masculino , Tasa de Depuración Metabólica , Pruebas de Sensibilidad Microbiana , Unión Proteica , Staphylococcus aureus/aislamiento & purificación , Staphylococcus epidermidis/aislamiento & purificaciónRESUMEN
OBJECTIVES: To determine the blood and tissue concentrations of flucloxacillin and amoxicillin during cardiopulmonary bypass (CPB) in infants weighing less than 5 kg. METHODS: Eleven patients aged between 3 and 60 days and weighing <5 kg. Intravenous flucloxacillin 30 mg kg(-1) and amoxicillin 30 mg kg(-1) were administered at time of anaesthesia. Blood and muscle samples were collected at four stages of the operation: immediately before commencement of CPB; before cross-clamping; after weaning of CPB; and at the time of skin closure. Concentrations, half-lives (t(1/2)), clearance and volume of distribution were calculated for both antibiotics in serum and tissue. RESULTS: After connection to CPB the mean serum concentration of flucloxacillin decreased by 42.5% from 75.5 to 43.4 mg l(-1) (P=0.003) and that of amoxicillin decreased by 36.2% from 73.3 to 46.7 mg l(-1) (P=0.021). Serum concentrations of the two antibiotics decreased by a further 16.5 and 14.5% during the remainder of the surgery, but remained >15-fold above the expected minimum inhibitory concentration (MIC) for target pathogens. Muscle concentrations of both antibiotics reached MIC values by the time of the first sample and there was no decrease associated with connection to CPB. Levels remained >8-fold above MIC for target pathogens throughout the procedure. The t(1/2) for flucloxacillin was 2.64(+/-0.23)h and for amoxicillin was 3.16(+/-0.29)h, both of which are more than double the values in normal adults. There was an equivalent reduction in clearance for both antibiotics. CONCLUSIONS: Single doses of flucloxacillin and amoxicillin at 30 mg kg(-1) maintain serum and muscle concentrations well above the MIC throughout cardiac surgery. This is partly due to a prolonged t(1/2) and reduced clearance of both antibiotics in infants.
Asunto(s)
Amoxicilina/farmacocinética , Antibacterianos/farmacocinética , Puente Cardiopulmonar , Floxacilina/farmacocinética , Cardiopatías Congénitas/cirugía , Amoxicilina/sangre , Antibacterianos/sangre , Profilaxis Antibiótica , Floxacilina/sangre , Semivida , Humanos , Lactante , Recién Nacido , Inyecciones Intravenosas , Periodo Intraoperatorio , Músculo Esquelético/metabolismoRESUMEN
BACKGROUND: Flucloxacillin is an important antimicrobial drug in the treatment of infections with Staphylococcus aureus and therefore is often used in staphylococcal infections. Furthermore, flucloxacillin has a high protein binding rate as for example ceftriaxone or teicoplanin--drugs which have formerly been characterized as not being dialyzable. METHODS: The pharmacokinetic parameters of 4.0 g flucloxacillin every 8 h were examined in 10 intensive care patients during continuous venovenous hemofiltration (CVVH) using a polyamide capillary hemofilter. In addition, the difficulty of calculating the hemofiltration clearance of a highly protein-bound drug is described. RESULTS: Flucloxacillin serum levels were significantly lowered (56.9 +/- 24.0%) even though only 15% of the drug was detected in the ultrafiltrate. Elimination half-life, total body clearance and sieving coefficient were 4.9 +/- 0.7 h, 117.2 +/- 79.1 ml/min and 0.21 +/- 0.09, respectively. These discrepancies can be explained by the high protein binding of flucloxacillin, the adsorbing property of polyamide and the equation in order to calculate hemofiltration clearance. The unbound fraction of a 4.0 g flucloxacillin dosage facilitates time above the minimum inhibitory concentration (T > MIC) of 60% only for strains up to a minimum inhibitory concentration (MIC) of 0.5 mg/l. CONCLUSION: Based on the data of this study, we conclude that intensive care patients with staphylococcal infections on CVVH should be treated with 4.0 g flucloxacillin every 8 h which was safe and well tolerated. Moreover, further studies with highly protein-bound drugs are recommended to check the classical 'hemodialysis' equation as the standard equation in calculating the CVVH clearance of highly protein-bound drugs.
Asunto(s)
Floxacilina/farmacocinética , Hemofiltración , Penicilinas/farmacocinética , Anciano , Área Bajo la Curva , Cuidados Críticos , Femenino , Floxacilina/sangre , Floxacilina/uso terapéutico , Semivida , Humanos , Masculino , Persona de Mediana Edad , Penicilinas/sangre , Penicilinas/uso terapéutico , Unión Proteica , Prueba Bactericida de Suero , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/metabolismoRESUMEN
Since the efficacy of beta-lactams against pathogens such as methicillin-susceptible Staphylococcus aureus (MSSA) is related to the time for which serum drug concentrations exceed the MIC for the pathogen, administration of anti-staphylococcal beta-lactams by continuous infusion may provide a more suitable means of drug delivery than intermittent dosing. To assess the clinical efficacy of continuous-infusion therapy, we reviewed the outcomes for 20 consecutive patients with proven serious MSSA sepsis (three with endocarditis, ten osteomyelitis, one endocarditis plus osteomyelitis and six deep abscess) treated with continuous-infusion flucloxacillin (8-12 g/day). Patients initially receiving routine intermittent-dose flucloxacillin therapy were changed to continuous-infusion flucloxacillin (mean duration 29 days; range 4-60 days) for completion of their treatment course. In the majority of cases this was given at home. Serum flucloxacillin concentrations during continuous-infusion flucloxacillin 12 g/day were 11.5->40 mg/L (ten patients) and those during continuous-infusion flucloxacillin 8 g/day were 8->40 mg/L (five patients), these concentrations being well above the expected MIC of flucloxacillin for MSSA. Continuous-infusion flucloxacillin was well tolerated by most patients, and 14/17 patients (82%) who completed their course of continuous-infusion flucloxacillin were judged clinically and microbiologically cured at long-term follow-up (mean 67 weeks; range 4-152 weeks). These preliminary data suggest that, following initial intermittent-dose flucloxacillin therapy, continuous-infusion flucloxacillin is an effective treatment option for serious MSSA sepsis, and forms a feasible and possibly preferable alternative to glycopeptides when considering home-based parenteral therapy for these infections. Further studies are needed to identify whether continuous-infusion flucloxacillin can entirely replace intermittent-dose therapy for such infections.
Asunto(s)
Floxacilina/administración & dosificación , Penicilinas/administración & dosificación , Sepsis/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Adolescente , Adulto , Anciano , Relación Dosis-Respuesta a Droga , Femenino , Floxacilina/sangre , Estudios de Seguimiento , Humanos , Infusiones Intravenosas , Masculino , Resistencia a la Meticilina , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Penicilinas/sangre , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/fisiología , Resultado del TratamientoRESUMEN
The present study assessed the suitability of the streptozotocin-treated diabetic rat as a model for the study of diabetes-impaired wound healing. The distribution of three antibiotics, ampicillin, benzylpenicillin, and flucloxacillin, in wound and adjacent tissue sites on the abdomens and legs of normal and diabetic rats was determined 30 min after intravenous administration of a single bolus containing 50 mg of all three antibiotics per kg of body weight. Tissue/plasma ratios showed that antibiotic tissue penetration appeared to be related to protein binding. The treatment of wound sites with vasodilators (1% solution) to increase local blood flow and antibiotic delivery to the site was then determined and appeared to be more effective with endothelium-independent sodium nitroprusside than with endothelium-dependent acetylcholine in diabetic rats. These results suggest that coadministration of topical vasodilators to wound sites in neuropathic diabetic patients undergoing antibiotic therapy for infected ulcers could increase antibiotic delivery to wound tissue sites.
Asunto(s)
Acetilcolina/farmacología , Ampicilina/farmacocinética , Diabetes Mellitus Experimental/metabolismo , Floxacilina/farmacocinética , Nitroprusiato/farmacología , Penicilina G/farmacocinética , Penicilinas/farmacología , Vasodilatadores/farmacología , Cicatrización de Heridas/fisiología , Heridas y Lesiones/metabolismo , Administración Tópica , Ampicilina/sangre , Animales , Cromatografía Líquida de Alta Presión , Diabetes Mellitus Experimental/fisiopatología , Modelos Animales de Enfermedad , Floxacilina/sangre , Masculino , Penicilina G/sangre , Ratas , Ratas Wistar , Distribución Tisular , Heridas y Lesiones/fisiopatologíaRESUMEN
The pharmacokinetics of dicloxacillin and flucloxacillin were studied in 12 healthy volunteers after oral administration. The participants received a single dose of either dicloxacillin (0.5 g, 0.75 g or 1.0 g) or flucloxacillin (0.75 g) in a cross-over fashion. Antibiotic concentrations were determined in serum and urine by bioassay and followed for 8 and 24 h, respectively. The three dicloxacillin dosages showed no significant differences for the serum elimination half-lives (t1/2 beta, median: 72 min). Comparing 0.75 g flucloxacillin with the same dose of dicloxacillin, no significant differences between the values of Cmax, t1/2 beta and AUC were found. Protein binding as determined by ultrafiltration in pooled serum was 94.7-96.2% for flucloxacillin and 96.4-97.2% for dicloxacillin. The serum bactericidal titers were similar for the two drugs. In conclusion, dicloxacillin and flucloxacillin showed similar pharmacokinetic behavior after 0.75 g doses in human volunteers.
Asunto(s)
Dicloxacilina/farmacocinética , Floxacilina/farmacocinética , Administración Oral , Adulto , Proteínas Sanguíneas/metabolismo , Estudios Cruzados , Dicloxacilina/administración & dosificación , Dicloxacilina/sangre , Relación Dosis-Respuesta a Droga , Femenino , Floxacilina/administración & dosificación , Floxacilina/sangre , Humanos , Masculino , Estudios Prospectivos , Unión Proteica , Staphylococcus aureus/efectos de los fármacos , UltrafiltraciónRESUMEN
The pharmacokinetics and oral bioavailability of flucloxacillin were studied in five female and two male patients (age 68-87 yr) who had been hospitalized for orthopedic surgeries. A single dose of intravenous or oral flucloxacillin sodium (500 mg) was administered in random order on different occasions separated by at least 2 days. Blood and urine samples were taken up to 24 hours after drug administration and levels of flucloxacillin and 5-hydroxymethylflucloxacillin (5-HMF), a major metabolite, were measured by high-performance liquid chromatography. Flucloxacillin elimination, but not oral absorption, was reduced in the elderly, compared with data from young healthy subjects reported elsewhere. Total clearance, renal clearance, and volume of distribution were 0.083 +/- 0.013 L/kg/hr, 0.038 +/- 0.01 L/kg/hr, and 0.184 +/- 0.034 L/kg, respectively. Regression of flucloxacillin renal clearance (Clr) on estimated creatine clearance (CLcr) gave the relationship: Clr = 0.755 (CLcr) + 10.6 (r = 0.91; P = 0.004). Terminal half-lives for flucloxacillin and 5-HMF were 2.21 +/- 0.51 hr and 3.0 +/- 0.75 hr, respectively after intravenous administration. Flucloxacillin was absorbed rapidly after oral administration with a mean absorption time of 0.95 +/- 0.34 hr, and time to reach peak concentration of 1.20 +/- 0.29 hr. The absolute bioavailability of flucloxacillin from capsules was 54.4 +/- 18.8%.